A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.

Publisher Website
Google Scholar
Abstract
Patients (11) with Huntington''s disease and 9 patients with tardive dyskinesia participated in a randomized double-blind crossover trial of sulpiride (as sole antidopaminergic therapy) vs. placebo. Although functional improvement was not seen in Huntington''s disease patients, sulpiride reduced movement count and total dyskinesia score in both conditions. Sulpiride differs pharmacologically, in several respects, from conventional neuroleptics, and has not been convincingly shown to cause tardive dyskinesia. Among currently available treatments, it may therefore be considered a drug of choice for treatment of tardive dyskinesia.

This publication has 10 references indexed in Scilit: